Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Metformin Placebo AND Metformin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    360 result(s) found for: Diabetes AND Metformin Placebo AND Metformin. Displaying page 9 of 18.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2011-003600-20 Sponsor Protocol Number: MK-0431E-211 Start Date*: 2012-08-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Co...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000669-21 Sponsor Protocol Number: 1218-0091 Start Date*: 2018-04-02
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) Outside EU/EEA DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-005892-83 Sponsor Protocol Number: WCH/2008/001 Start Date*: 2009-01-14
    Sponsor Name:Epsom and St Helier University Hospitals NHS Trust
    Full Title: Does metformin improve pregnancy outcomes [ incidence of LGA (≥90% birth weight centile) babies onset of maternal Gestational Diabetes, hypertension, PET, shoulder dystocia, admission to SCBU) in o...
    Medical condition: Obesity in pregnancy. Obesity in pregnancy has been identified by Confidential Enquiry into Maternal And Child Health (CEMACH) (2008-2011) as a major health risk to mother and baby.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003956-12 Sponsor Protocol Number: NN9535-1821 Start Date*: 2008-04-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with m...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) FI (Completed) FR (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004179-33 Sponsor Protocol Number: I8F-MC-GPGB Start Date*: 2017-06-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001779-22 Sponsor Protocol Number: 04.2017 Start Date*: 2017-07-10
    Sponsor Name:Aarhus University Hospital, Department of Endocrinology
    Full Title: The Effect of Empagliflozin on Cardiac and Kidney Metabolism in Persons with Type 2 Diabetes
    Medical condition: Diabetes, type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-001392-37 Sponsor Protocol Number: 0431-053 Start Date*: 2006-07-21
    Sponsor Name:Merck Sharp & Dohme GesmbH
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Me...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003697-26 Sponsor Protocol Number: MK8835-006 Start Date*: 2014-07-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of ...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin and sitagliptin.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) FI (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003290-95 Sponsor Protocol Number: 8835-007 Start Date*: 2014-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MEL...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-000859-40 Sponsor Protocol Number: AIFA-2016-02364864 Start Date*: 2018-11-07
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to ad...
    Medical condition: Type-2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012597-13 Sponsor Protocol Number: DUT-MD-303 Start Date*: 2009-11-19
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment wit...
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-001538-41 Sponsor Protocol Number: Start Date*: 2011-06-29
    Sponsor Name:University of Birmingham
    Full Title: The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control
    Medical condition: This trial will investigate the effects of the study treatment arms (gastric band + placebo; gastric band + liraglutide) on diabetes resolution in obese patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002739-24 Sponsor Protocol Number: 60 Start Date*: 2011-08-30
    Sponsor Name:Dr. med. Tina Vilsbøll
    Full Title: Does the GLP-1 receptor agonist (Victoza®) improve the metabolic response to physical training in patients with type 2 diabetes?
    Medical condition: Diabetes type 2
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003189-26 Sponsor Protocol Number: Version1.2 Start Date*: 2014-12-01
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Metformin and its Effects on Myocardial Dimension and Left ventricular hypertrophy in normotensive patients with Coronary Artery Disease.
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10022489 Insulin resistance PT
    17.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    17.0 100000004849 10025164 LVH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016366-88 Sponsor Protocol Number: 28431754DIA3002 Start Date*: 2010-05-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type ...
    Medical condition: type 2 diabetes mellitus (T2DM) with inadequate glycemic control on combination therapy with metformin and a sulphonylurea (SU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005196-16 Sponsor Protocol Number: H8O-MC-GWBQ Start Date*: 2012-07-24
    Sponsor Name:Amylin Pharmaceuticals, Inc.
    Full Title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes
    Medical condition: Treatment of Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005809-20 Sponsor Protocol Number: BC22092 Start Date*: 2009-01-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in obese patients with type 2 diabe...
    Medical condition: Patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003738-25 Sponsor Protocol Number: ESR-16-12160/UKE-DapEx-001 Start Date*: 2017-12-28
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared...
    Medical condition: Obese insulin-resistant patients with Type 2 Diabetes mellitus (T2DM) and inadequate glycemic control (HbA1c ≥ 8.0% and ≤ 11.0%)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003640-11 Sponsor Protocol Number: MK0431C-102 Start Date*: 2008-10-30
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Medical condition: Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed) AT (Completed) LT (Completed) EE (Completed) LV (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000988-16 Sponsor Protocol Number: NN9924-4280 Start Date*: 2016-12-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes Mellitus treated with insulin - A 52-week, randomised, placebo-controlled trial, double-blinded during the in...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:37:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA